Austin, Texas, United States, March 6th, 2026, FinanceWire
- Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages.
- Soligenix’s development of synthetic hypericin illustrates this “one drug, multiple diseases” model in action.
- HyBryte is being developed to treat both cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin, and psoriasis.
Modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. Rather than building entirely new molecules for every indication, companies are developing platform technologies that allow a single therapeutic approach to be adapted across conditions. Soligenix 
SNGX exemplifies this strategy through its use of synthetic hypericin across two distinct dermatologic indications, illustrating how platform science can streamline development and expand clinical impact.
Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages. In drug development, platform technology is a foundational technology or system that serves as a base for the development of multiple products, solutions or…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
Contact
IBN
512.354.7000 Office
www.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com